July 5, 2022
Vickers Vantage I : Announces Shareholder Approval of Extension of Deadline to Complete Business Combination – Form 8-K
April 11, 2022
Vickers Vantage Corp. I Extends Time to Complete Business Combination
April 4, 2022
Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., announces continuous sales growth in ZTlido® with preliminary gross sales of approximately $8.1 million during the month of March 2022 and $18.4 million for 1Q2022
March 25, 2022
Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., enters into a Non-Binding Term Sheet for a $5 Billion Committed Equity Financing Facility to be Effective in Connection with the Closing of the Merger with Vickers Vantage Corp I
March 17, 2022
Scilex Holding Company a Majority Owned Subsidiary of Sorrento Therapeutics Inc to Become Publicly Traded Through a Merger With Vickers Vantage Corp I
January 7, 2022
December 6, 2021
Scilex Holding Company, a Sorrento Therapeutics Inc. Subsidiary, and Vickers Vantage Corp I (NASDAQ: VCKA) (“SPAC”) Enter into Letter of Intent for Proposed Business Combination
June 1, 2021
Vickers Vantage Corp. I Receives Nasdaq Notification Of Non-Compliance With Listing Rules
March 5, 2021
Vickers Vantage Corp. I Announces the Separate Trading of its Common Stock and Warrants, Commencing March 3 2021
January 11, 2021
Vickers Vantage Corp. I Announces Closing of $138,000,000 Initial Public Offering
